1 June 2018 in Parkinsonism & Related Disorders
30 June 2023 in Journal of Neurology, Neurosurgery & Psychiatry
Background The choroid plexus (CP) is involved in the clearance of harmful metabolites from the brain, as a part of the glymphatic system. This study aimed to investigate the association between CP volume (CPV), nigrostriatal dopaminergic degeneration and motor outcomes in Parkinson’s disease (PD). Methods We retrospectively searched drug-naïve patients with early-stage PD who underwent dopamine transporter (DAT) scanning and MRI. Automatic CP segmentation was performed, and the CPV was calculated. The relationship between CPV, DAT availability and Unified PD Rating Scale Part III (UPDRS-III) scores was assessed using multivariate linear regression. We performed longitudinal analyses to assess motor outcomes according to CPV. Results CPV was negatively associated with DAT availability in each striatal subregion (anterior caudate, β=−0.134, p=0.012; posterior caudate, β=−0.162, p=0.002; anterior putamen, β=−0.133, p=0.024; posterior putamen, β=−0.125, p=0.039; ventral putamen, β=−0.125, p=0.035), except for the ventral striatum. CPV was positively associated with the UPDRS-III score even after adjusting for DAT availability in the posterior putamen (β=0.121; p=0.035). A larger CPV was associated with the future development of freezing of gait in the Cox regression model (HR 1.539, p=0.027) and a more rapid increase in dopaminergic medication in the linear mixed model (CPV×time, p=0.037), but was not associated with the risk of developing levodopa-induced dyskinesia or wearing off. Conclusion These findings suggest that CPV has the potential to serve as a biomarker for baseline and longitudinal motor disabilities in PD.
19 July 2019 in Movement Disorders
Background: Growing evidence suggests an association between imaging biomarkers of small vessel disease and future cognitive decline in Parkinson's disease (PD). Recently, magnetic resonance imaging–visible perivascular space (PVS) has been considered as an imaging biomarker of small vessel disease, but its effect on cognitive decline in PD is yet to be investigated.Objective: The objective of this study was to evaluate whether PVS can independently predict cognitive decline in PD.Methods: A total of 271 PD patients were divided into 106 patients with intact cognition (PD‐IC) and 165 patients with mild cognitive impairment (PD‐MCI). After a mean follow‐up of 5.0 ± 2.3 years, 18 PD‐IC patients showed cognitive decline to PD‐MCI and 34 PD‐MCI patients showed cognitive decline to dementia. PVS was rated in the basal ganglia (BG) and centrum semiovale using a 4‐point visual scale and then classified as high (score ≥ 2) or low (score < 2) according to severity. Lacunes and white matter hyperintensity severity were also assessed. Independent risk factors for cognitive decline were investigated using multivariable logistic regression analysis.Results: In all patients, higher BG‐PVS and white matter hyperintensity severity, higher levodopa‐equivalent dose, hypertension, and lower Mini‐Mental State Examination score were independent positive predictors of future cognitive decline. In the PD‐IC subgroup, higher BG‐PVS severity, hypertension, and more severe depressive symptoms were predictors of cognitive conversion. In the PD‐MCI subgroup, higher BG‐PVS and white matter hyperintensity severity, and lower Mini‐Mental State Examination score were predictors of cognitive decline.Conclusions: BG‐PVS may be a useful imaging marker for predicting cognitive decline in PD. © 2019 International Parkinson and Movement Disorder Society
6 August 2023 in European Journal of Neurology
1 March 2021 in Nutrition
24 February 2020 in Movement Disorders